Can a lactating mother safely breastfeed while taking Vyvanse (lisdexamfetamine) and Wellbutrin (bupropion)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Breastfeeding While Taking Vyvanse and Wellbutrin

Yes, you can breastfeed while taking both Vyvanse (lisdexamfetamine) and Wellbutrin (bupropion), though both medications require careful infant monitoring for specific adverse effects.

Vyvanse (Lisdexamfetamine) and Breastfeeding

Lisdexamfetamine is compatible with breastfeeding based on amphetamine class data, with a Hale lactation risk category of L3. 1

Key Evidence for Amphetamines During Lactation

  • Lisdexamfetamine is a prodrug that converts to dextroamphetamine, so amphetamine breastfeeding data directly applies 1
  • Therapeutic amphetamine use during lactation does not appear to adversely affect infants 1
  • Amphetamines are present in breast milk at relative infant doses of 2% to 13.8% of the maternal weight-adjusted dosage, with milk/plasma ratios ranging from 1.9 to 7.5 2
  • The FDA label notes that while amphetamines are present in human milk, there are no reports of adverse effects on breastfed infants from published case reports 2

Required Infant Monitoring for Vyvanse

Monitor your infant carefully for: 1

  • Irritability
  • Insomnia or sleep disturbances
  • Feeding difficulties
  • Poor weight gain

Wellbutrin (Bupropion) and Breastfeeding

Bupropion can be used during breastfeeding with caution, though data are very limited (only 21 published cases). 1

Key Evidence for Bupropion During Lactation

  • Bupropion is present in human milk and has been detected in infant serum at very low levels (sometimes undetectable) 1
  • Generally no adverse events have been reported in most cases 1
  • Critical safety concern: There have been 2 case reports of seizures in breastfed infants exposed to bupropion 1

Required Infant Monitoring for Wellbutrin

Monitor your infant carefully for: 1

  • Vomiting
  • Diarrhea
  • Jitteriness
  • Sedation
  • Seizures (most serious concern)

Combined Use Considerations

When taking both medications simultaneously while breastfeeding:

  • Both medications transfer into breast milk, creating cumulative infant exposure to stimulant effects 1, 2
  • The combination increases the importance of vigilant infant monitoring for CNS stimulation (irritability, jitteriness, insomnia) 1
  • Weight gain and feeding patterns require close attention, as both medications can potentially affect these parameters 1, 2

Clinical Decision Framework

The decision to breastfeed on these medications should prioritize:

  1. Maternal mental health and quality of life: Untreated ADHD and depression significantly impair maternal functioning and bonding 1
  2. Infant safety monitoring: Establish a clear monitoring plan with your pediatrician before continuing breastfeeding 1
  3. Benefits of breastfeeding: The immunologic, developmental, and bonding benefits of breastfeeding are substantial 3, 4, 5

Practical Monitoring Plan

  • Schedule frequent pediatric follow-ups in the first weeks of combined medication use 1
  • Document infant sleep patterns, feeding duration/frequency, and weight gain weekly 1, 2
  • Immediately contact your pediatrician if seizure activity, severe irritability, or feeding refusal occurs 1
  • Consider timing breastfeeding sessions to occur when maternal drug levels are lowest (just before next dose) to minimize infant exposure 6, 5

Important Caveats

  • The FDA label for lisdexamfetamine states that "breastfeeding is not recommended during treatment," citing potential for serious cardiovascular reactions, blood pressure increases, growth suppression, and peripheral vasculopathy 2
  • However, the 2024 American Journal of Obstetrics and Gynecology guidelines provide more nuanced guidance supporting breastfeeding with monitoring for therapeutic amphetamine use 1
  • This represents a divergence between FDA labeling (which takes a maximally cautious approach) and clinical practice guidelines (which weigh maternal benefits against infant risks) 1, 2
  • Large doses of dextroamphetamine might interfere with milk production, especially in women whose lactation is not well established 2

References

Guideline

attention-deficit/hyperactivity disorder in pregnancy and the postpartum period.

American Journal of Obstetrics and Gynecology, 2024

Research

Minimizing infant exposure to and risks from medications while breastfeeding.

The Journal of perinatal & neonatal nursing, 1997

Research

Medications and breast-feeding: Current concepts.

Journal of the American Pharmacists Association : JAPhA, 2012

Related Questions

Is Dicycloamine (anticholinergic medication) safe to use during lactation, especially in newborns or premature infants?
Are diuretics, such as furosemide (Lasix) and hydrochlorothiazide (HCTZ), safe to use during breastfeeding?
Is it safe for a breastfeeding mother to receive a Glutathione (reduced glutathione) infusion?
Is Jardiance (empagliflozin) safe to use during breastfeeding?
Can a breast-feeding patient take Robitussin DM (dextromethorphan and guaifenesin) and time it to minimize the amount of medication that enters the breast milk?
Should patients with chronic heart failure and SIADH be treated with salt tablets?
How should rosuvastatin be managed in a patient with acute kidney injury (AKI) and reduced estimated glomerular filtration rate?
What do the colony‑forming unit (CFU) counts on a urine culture represent, and does a higher count indicate a better outcome?
What is the recommended dosing and administration of Dulcolax (bisacodyl) suppositories for adults and children, including contraindications and duration of use?
In a patient without prior treated syphilis or severe immunosuppression, how conclusive are a negative rapid plasma reagin (RPR) at 41 days and a negative treponemal test at 55 days after presumed exposure for ruling out primary or early secondary syphilis?
What is the appropriate diagnostic work‑up and management for a patient with new central mesenteric and retroperitoneal mild adenopathy with surrounding mesenteric inflammation/stranding, considering sclerosing mesenteritis versus lymphoma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.